Newscasting from ACC 2024 - Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes
An analysis of data from PARADIGM-HF suggests sacubitril/valsartan (Entresto) provided consistent benefit across the spectrum of renal impairment among patients with heart failure with reduced ejection fraction (HFrEF).
Presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, the study assessed the effects of the angiotensin receptor–neprilysin inhibition across the recently published 2024 Kidney Disease Improving Global Outcomes (KDIGO) classifications, with results supporting use in patients with HFrEF across the spectrum of kidney risk included in PARADIGM-HF.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
